Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
OphthaFund is an early-stage investment organization founded in 2019, based in the United States. The firm focuses on the ophthalmology and life sciences sectors, connecting investors with innovative ideas and startups. OphthaFund provides extensive research into intellectual property, company guidance, and market analysis to support emerging technologies.
Currently, OphthaFund manages a portfolio of six companies and operates with a team of experienced professionals. The firm emphasizes a meticulous approach to due diligence, which has been instrumental in identifying ventures with strong market potential and clear pathways to commercialization. Notable milestones include the successful acquisition of Encore Pharmaceuticals by Novartis, showcasing the firm's ability to identify promising investments.
OphthaFund invests primarily in early-stage companies within the ophthalmology and biotechnology sectors. The firm targets investments at the Seed, Series A, and Series B stages, focusing on ventures that demonstrate strong market potential and clear commercialization pathways. Their investment strategy is characterized by a rigorous due diligence process, which helps in assessing the viability and growth prospects of potential investments.
The organization seeks to partner with founders who possess innovative ideas and a solid understanding of their market. OphthaFund's emphasis on thorough research and analysis allows them to identify opportunities that align with their investment thesis, particularly in the rapidly evolving healthcare landscape.
OphthaFund's portfolio includes six companies, showcasing a strong focus on biotechnology and ophthalmology. The notable companies in their portfolio are:
This diverse portfolio reflects OphthaFund's commitment to supporting innovative companies in the healthcare sector, particularly those focused on ophthalmology.
George Magrath: Co-Founder & Venture Principal. George has extensive experience in venture capital and has led multiple investments in the biotechnology sector.
Tom Mather: Co-Founder & Venture Principal. Tom brings a wealth of knowledge in early-stage investments and has a strong background in healthcare.
Andrea Marshall: Co-Founder & Managing Principal. Andrea has a deep understanding of the ophthalmology market and has been instrumental in shaping OphthaFund's investment strategy.
Jay Thompson, MD: Ophthalmologist Advisor. Jay provides clinical insights and guidance on ophthalmology-related investments.
Paul Ryb: Investment Banking Advisor. Paul offers expertise in financial structuring and market analysis.
Mark Volkmann: Operating Advisor. Mark supports portfolio companies with operational strategies and growth initiatives.
Rich Sanchez: Investor Relations Advisor. Rich manages relationships with investors and stakeholders, ensuring effective communication and engagement.
OphthaFund prefers startups to submit their pitches through the contact form on their website. Founders should include a comprehensive deck that outlines their business model, market analysis, and growth potential. Response times may vary, but the firm encourages warm introductions when possible to facilitate the process.
In recent months, OphthaFund has been actively involved in connecting investors with innovative ideas in the ophthalmology sector. The firm continues to provide extensive research into intellectual property and market analysis for startups.
OphthaFund's notable exit includes the acquisition of Encore Pharmaceuticals by Novartis, highlighting the firm's ability to identify and support high-potential investments.
What are OphthaFund's investment criteria?
OphthaFund focuses on early-stage companies in the ophthalmology and biotechnology sectors. They look for ventures with strong market potential and clear pathways to commercialization.
How can startups apply or pitch to OphthaFund?
Startups can reach out through the contact form on OphthaFund's website. They should provide detailed information about their business model, market analysis, and potential for growth.
What makes OphthaFund different from other venture capital firms?
OphthaFund emphasizes a meticulous approach to due diligence, which helps them identify high-potential investments in the ophthalmology sector. Their deep expertise in this niche market sets them apart.
What is the geographic scope of OphthaFund's investments?
The firm primarily invests in companies based in the United States, focusing on the ophthalmology and biotechnology sectors.
What is OphthaFund's post-investment involvement like?
OphthaFund provides guidance and support to portfolio companies, leveraging their expertise in the ophthalmology sector to help startups navigate challenges and achieve growth.
What is the typical check size for investments made by OphthaFund?
OphthaFund invests at the Seed, Series A, and Series B stages, with check sizes varying based on the specific needs and potential of each company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.